Physician profile
Malorie M Mann
NPI 1417601444
$2,317.74
in general payments reported to CMS, 2019-2025
16 companies · $937 in 2025
The $937 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.17 · 2023: $619 · 2024: $714 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.72 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $931.55 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $618.75 | 2023-2025 | |
| Alkermes, INC. | $223.12 | 2022-2025 | Vivitrol, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.48 | 2025 | Caplyta |
| Indivior INC. | $113.40 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $52.34 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $36.76 | 2024 | Epclusa |
| Pfizer INC. | $33.53 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.43 | 2023 | |
| Braeburn INC. | $26.05 | 2023 | Brixadi |
| Vanda Pharmaceuticals INC. | $23.33 | 2025 | Fanapt |
| Currax Pharmaceuticals LLC | $15.09 | 2023 | Contrave |
| Astellas Pharma US INC | $13.93 | 2024 | Veozah |
| Novo Nordisk INC | $13.40 | 2024 | Wegovy |
| Lilly USA, LLC | $13.36 | 2024 | Zepbound, Mounjaro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surmodics, INC. | $9.22 | 2024 | Pounce Thrombectomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malorie Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.